| 23/245 |
Annual Reports & Financial Statements |
| 23/244 |
Immunoglobulin Drugs |
| 23/243 |
Medicines |
| 23/242 |
Clotting Disorders |
| 23/241 |
Assaults on Staff |
| 23/240 |
Guidelines for Idiopathic Pulmonary Fibrosis |
| 23/239 |
Active Transport |
| 23/237 |
Asthma |
| 23/236 |
Digital Dictation, Speech Recognition, Outsourced Transcription and Video Consultation |
| 23/235 |
Treatment of Haemophilia A |
| 23/234 |
New Hospital Funding |
| 23/233 |
Estates & Facilities |
| 23/232 |
Email Archive |
| 23/231 |
Healthcare Waste |
| 23/230 |
Off Framework |
| 23/228 |
E-consent Digital Communications |
| 23/225 |
A&E Patients |
| 23/222 |
Nivolumab |
| 23/220 |
Dabrafenib + Trametinib in Cancer Treatment |
| 23/219 |
Tech Contract Expiry Update |
